Back to search

Article

Clinical Efficacy and Safety of Anti-vascular Biosimilars Compared to Reference Anti-vascular for neovascular age-related macular degeneration: A Systematic Review, Meta-Analysis and Meta-regression.

2025-12-03

Abstract excerpt

<title>Abstract</title> <p>Background Neovascular age-related macular degeneration (nAMD) is a leading cause of irreversible vision loss in older adults and is commonly treated with intravitreal anti-VEGF agents such as ranibizumab and aflibercept. These therapies are highly effective but expensive, imposing a significant burden on patients and healthcare systems. Biosimilars offer a lower-cost alternative, but c...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
d0e52a15-2b41-5134-bf4f-3fc75daebecf
DOI
10.21203/rs.3.rs-7909324/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Clinical Efficacy and Safety of Anti-vascular Biosimilars Compared to Reference Anti-vascular for neovascular age-related macular degeneration: A Systematic Review, Meta-Analysis and Meta-regression.DOI 10.21203/rs.3.rs-7909324/v1
Short-Term Efficacy of Aflibercept 8 mg in Refractory Neovascular Age-Related Macular Degeneration: A Real-World Retrospective Case Series from TaiwanSemantic proximity
Eighteen-Month Real-World Outcomes of Intravitreal Aflibercept 8 mg in Treatment-Naïve Neovascular Age-Related Macular Degeneration: A UK Single- Centre ExperienceSemantic proximity
Sequential switch from first-line anti-VEGF therapy to faricimab and subsequent aflibercept 8mg in treatment-resistant neovascular AMDSemantic proximity
Extended Duration Anti-VEGF Therapy for Chorioretinal Vascular Diseases: Successes, Failures and ChallengesSemantic proximity
The Moorfields AMD Database Report 2 - Fellow Eye Involvement with Neovascular Age-related Macular DegenerationSemantic proximity
Dual pathway inhibition with faricimab for previously treated neovascular age-related macular degeneration and diabetic macular oedema: Guidance from a UK panel of retina specialistsSemantic proximity
Relationship between Aflibercept Efficacy and Genetic Variants of Genes Associated with Neovascular Age-Related Macular Degeneration: The BIOIMAGE Trial.Semantic proximity
Effects of aflibercept for ranibizumab-resistant neovascular age-related macular degeneration and polypoidal choroidal vasculopathy.Semantic proximity
Clinical care and therapeutic practice of patients with neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME) and effectiveness of faricimab in treatment-naive patients in Germany - ZEUS research projectSemantic proximity
Predictors of anti-VEGF treatment response in neovascular age-related macular degenerationSemantic proximity
Two-year visual outcome of ranibizumab in typical neovascular age-related macular degeneration and polypoidal choroidal vasculopathy.Semantic proximity
Polymorphisms in vascular endothelial growth factor receptor 2 are associated with better response rates to ranibizumab treatment in age-related macular degeneration.Semantic proximity
Select a neighboring publication to make it the new centre.